Interpretable extracellular vesicle long RNA framework for noninvasive pancreatic cancer diagnosis: A multi-omics artificial intelligence-driven liquid biopsy paradigm

Abstract

Diagnosing pancreatic ductal adenocarcinoma at an early stage is highly challenging, which largely drives its persistently high mortality rate. Recently, an interpretable machine learning framework known as ECD-itMLF was introduced to tackle this issue. By analyzing plasma extracellular vesicle (EV) long RNAs, the model achieved an impressive area under the curve of 0.9698 for early detection. In this opinion review, we examine this framework's breakthroughs against the broader backdrop of artificial intelligence-driven multi-omics, while also reviewing the latest progress in EV biology and extraction techniques. Crucially, we argue that such models must be strictly tested against common clinical confounders—especially diabetes and obstructive jaundice—before they can be trusted. We also urge a shift toward more actionable clinical metrics, such as positive predictive values and decision curve analysis. Finally, to address modern oncology’s need for intuitive data interpretation, we outline comprehensive multi-omics strategies and integrated diagnostic blueprints. While the ECD-itMLF paradigm shows tremendous promise, we also look ahead to its potential in monitoring minimal residual disease and advancing single-EV technologies, cautioning that rigorous standardization remains mandatory before everyday clinical use.

Key Words: Pancreatic ductal adenocarcinoma; Extracellular vesicles; Long RNA; Interpretable artificial intelligence; Liquid biopsy; Multi-omics; Interpretable machine learning

Core Tip: We examine the ECD-itMLF interpretable machine learning model, which recently achieved a remarkable area under the curve of 0.9698 for early pancreatic ductal adenocarcinoma detection using sparse extracellular vesicle long RNA data. Despite this excellent performance, moving the tool into the clinic requires testing it against common patient variables like diabetes and jaundice. In this article, we break down the model’s explainable artificial intelligence roots and present visual summaries of current multi-omics research. Looking ahead, we discuss how this extracellular vesicle-based approach could be adapted for tracking minimal residual disease and integrating multiple analytes, providing a realistic path from the lab to everyday precision oncology.

INTRODUCTION

Pancreatic ductal adenocarcinoma (PDAC) is an advanced and intractable disease with rare early stage symptoms. Therefore, around 80% of patients are diagnosed at advanced or metastatic stages, and thus cannot undergo curative surgery[1,2]. While imaging modalities and molecular biology are making progress, the early detection of PDAC remains a challenge[3]. Most commonly used markers, such as carbohydrate antigen 19-9, are not sensitive enough for early-stage disease, and are prone to false positives due to benign disease conditions such as chronic pancreatitis[4,5].

The overall burden of PDAC continues to increase, and the 5-year survival rate remains low, with a worldwide average of around 10%[6,7]. Modern imaging modalities are essential for staging PDAC, but they are less sensitive for detecting sub-centimeter pancreatic lesions[8]. Furthermore, microscopic precursor lesions (such as pancreatic intraepithelial neoplasia) are usually not well resolved by current imaging methods[9], and their invasive nature and cost have not well evaluated for population screening. Liquid biopsy technologies [e.g., based on extracellular vesicles (EVs)] have emerged as a promising direction for noninvasive diagnostics[10,11]. Compared with circulating tumor DNA (ctDNA), which is typically limited by low shedding and limited tumor burden in early stages[12], and circulating tumor cells, which are rare in peripheral blood and are difficult to detect reliably in early stage[13], EVs present several benefits: They are abundant in circulation and fairly stable because of lipid bilayer protection, and carry molecular cargo corresponding to their mother cells[14-16]. EVs store a wealth of biomolecular information, such as long noncoding RNAs that reflect the physiological and pathological status of mother cells[17].

Recent technological advances have enabled rapid development in EV based diagnosis. Machine learning algorithms for analyzing high-dimensional, sparse omics data have been able to detect a very interesting molecule[18,19]. However, the “black box” nature of many artificial intelligence (AI) models has impeded clinical adoption, creating demand for interpretable frameworks that balance predictive accuracy with biological transparency[20,21].

A recent study published by Liu and Zhang[22] introduced an interpretable two-layer machine learning framework (ECD-itMLF) based on plasma EV long RNA (EV-lRNA). Their work addresses critical gaps in both diagnostic accuracy and algorithmic transparency. We commend the authors on their methodological innovation, particularly the construction of the “EV-lRNA-index”. Distinguishing PDAC from chronic pancreatitis is quite challenging, particularly when handling highly sparse, high-dimensional RNA-seq data. Rather than relying on a single method, the ECD-itMLF approach merged three specific tools—singular value decomposition, nonlinear iterative partial least squares, and probabilistic principal component analysis—to compress the data space. The result was a remarkable area under the curve (AUC) of 0.9698. What makes this model superior to conventional techniques is how it handles interference. It discards background noise without sacrificing the actual biological context, translating directly into a robust tool for patient risk stratification.

CELL-DERIVED EV BIOLOGY AND ISOLATION

EV heterogeneity and cargo complexity

Almost all cells naturally shed EVs, creating a highly diverse mix of membrane-bound particles within the body[23,24]. Historically, researchers have divided these vesicles into three main groups based on how they form. Exosomes, which measure between 30 and 150 nm, are released from multivesicular bodies. Meanwhile, microvesicles (100-1000 nm) pinch directly off the plasma membrane, and much larger apoptotic bodies (1-5 μm) break away when a cell undergoes programmed death[25,26]. For pancreatic cancer specifically, tumor-derived EVs are incredibly valuable because they act as miniature molecular replicas, carrying the exact biological blueprints of the PDAC cells that secreted them. The tumor microenvironment in PDAC, characterized by extensive desmoplasia and hypoxia, influences EV cargo composition[27,28]. Tumor cell-derived EVs can be detected in circulation even at early disease stages, potentially overcoming the limitation of low ctDNA shedding rates in localized PDAC[29].

Isolation methodologies and standardization

The translation of EV-based diagnostics to clinical practice faces significant pre-analytical challenges. The Minimal Information for Studies of Extracellular Vesicles guidelines provide updated recommendations for EV isolation and characterization, emphasizing the need for method validation and reporting standards[30]. Historically, researchers relied heavily on ultracentrifugation as the “gold standard” for EV isolation. However, we now know that it has major drawbacks, particularly its low throughput and the frustrating tendency to co-isolate lipoproteins[31,32]. Although achieving reproducible results by size-exclusion chromatography heavily depends on rigorous column standardization, the method remains excellent for recovering highly pure fractions[33,34]. On a different front, emerging affinity capture techniques bypass general isolation entirely; instead, they target distinct EV subpopulations by binding to specific tetraspanin markers like CD81, CD63, and CD9. The catch here is that they inherently introduce antibody-driven biases[35,36]. Ultimately, if we want to bring any of these methods into routine clinical use, the field must shift toward automated, standardized platforms to eliminate the variability that inevitably comes with human operators[37,38].

RNA species in EVs

We used to think of EV cargo primarily in terms of microRNAs (miRNAs), but deep profiling has completely upended that view. We now know that these vesicles are packed with a vast array of transcripts, including messenger RNAs, long non-coding RNAs, circular RNAs, and other small RNAs[39-41]. When it comes to pancreatic cancer (PDAC), miRNAs certainly have the longest track record. However, because isolated miRNAs consistently fail on diagnostic specificity, researchers have pivoted to multi-marker panels—such as combinations of miR-21, miR-155, and miR-10b—with much better clinical success[42]. Lately, the spotlight has decisively shifted toward long non-coding RNAs. Detecting heavy hitters like metastasis-associated lung adenocarcinoma transcript-1 and Hox transcript antisense intergenic RNA inside EVs not only flags active tumor progression but also provides highly robust clinical readouts[43,44]. Add to this the surprising extracellular stability of messenger RNAs and circular RNAs[45,46], and the path forward becomes clear: We need to stop looking at these molecules in isolation. By integrating multiple RNA classes through a comprehensive multi-omics lens, we can drastically sharpen our diagnostic accuracy[47,48].

AI-DRIVEN MULTI-OMICS INTEGRATION

Machine learning applications in liquid biopsy

The sheer volume and complexity of modern cancer datasets have pushed researchers past the limits of conventional biostatistics, making artificial intelligence an absolute necessity[49]. This is especially true for liquid biopsies. Here, AI algorithms easily chew through high-dimensional molecular readouts to identify subtle diagnostic signatures that standard models routinely miss[50,51]. Furthermore, since we are usually forced to work with relatively small clinical cohorts, supervised learning techniques—particularly support vector machines and random forests—have become the go-to tools for extracting reliable insights without overfitting the data. These models remain popular because they perform reliably and allow researchers to easily interpret the results[52,53]. Conversely, while deep learning frameworks provide exceptional accuracy when applied to very large datasets, they come with the trade-off of demanding heavy computational resources[54].

The interpretability imperative in clinical AI

One of the biggest hurdles for bringing AI into clinical practice is the well-known “black box” issue. Even when these models are highly accurate, it is often unclear how they arrive at their predictions[55,56]. Because treatment decisions in oncology are so critical, doctors absolutely need to understand the reasoning behind a model’s output[57]. To make these tools more transparent, researchers increasingly rely on explainable AI techniques, particularly feature attribution tools like SHapley Additive exPlanation values[58,59]. Going a step further, frameworks such as ECD-itMLF do not just look at statistical correlations; they link important predictive features directly to known biological processes, like the epithelial-mesenchymal transition[22]. Furthermore, by cross-referencing these findings with single-cell RNA sequencing data, researchers can trace the likely cellular origins of the detected signals. This biological grounding ultimately gives clinicians much more confidence in the AI's results[60,61].

Dimensionality reduction for sparse omics data

The classic “curse of dimensionality” is a notorious problem in EV-RNA sequencing, primarily because the sheer volume of measured variables drastically outnumbers the available samples, leading directly to overfitting risks[62,63]. The ECD-itMLF framework overcomes this mathematical bottleneck by integrating three different dimensionality reduction tools. Specifically, it uses singular value decomposition to cut through linear noise, alongside nonlinear iterative partial least squares to capture non-linear relationships. Furthermore, probabilistic principal component analysis is incorporated to directly model observation noise[64]. Ultimately, weaving these three algorithms together creates a much more reliable pipeline for navigating complex omics datasets[22].

To systematically illustrate how raw omics data is mathematically transformed into an explainable diagnostic output, Figure 1 delineates the conceptual workflow of this interpretable machine learning approach.

Figure 1 Conceptual workflow of the interpretable two-layer machine learning framework (ECD-itMLF) for pancreatic ductal adenocarcinoma diagnosis. Created with Picdoc. A: Plasma extracellular vesicle isolation and long RNA sequencing; B: Dimensionality reduction layer integrating singular value decomposition, nonlinear iterative partial least squares, and probabilistic principal component analysis to construct the extracellular vesicle long RNA-index; C: Two-layer classification strategy with support vector machine screening followed by random forest differentiation; D: Biological interpretability through pathway enrichment and single-cell correlation analysis. EV: Extracellular vesicle; EV-lRNA: Extracellular vesicle long RNA; SVD: Singular value decomposition; NIPALS: Nonlinear iterative partial least squares; PPCA: Probabilistic principal component analysis; SVM: Support vector machine; PDAC: Pancreatic ductal adenocarcinoma; EMT: Epithelial-mesenchymal transition; TGF-β: Transforming growth factor-β.

CRITICAL ASSESSMENT AND CLINICAL TRANSLATABILITY

Since systemic inflammation, diabetes, and obstructive jaundice occur with extremely high prevalence among patients with PDAC, we must take the assessment of these prevalent concurrent disorders as our top clinical priority, for such underlying conditions are nearly ubiquitous in this patient cohort. Until we navigate these messy, real-world health profiles, taking these impressive statistical yields and applying them directly in a hospital setting remains premature. Because hyperbilirubinemia and blood sugar fluctuations actively alter both EV release and their internal cargo, researchers must verify that the EV-lRNA signature remains stable under these conditions[65].

Evaluating performance in a real-world context

Achieving an AUC of 0.9698 when separating PDAC from chronic pancreatitis is an excellent result. However, the true test of this diagnostic tool lies in early detection. Because stage I tumors typically release a much lower volume of EVs with different cargo profiles[66], the model’s sensitivity for early-stage disease requires strict prospective validation.

Moving beyond AUC for clinical utility

Finally, a high AUC is simply a summary of discrimination; it is not enough to guide daily medical decisions. Doctors require well-calibrated probability estimates to trust a model[67]. Furthermore, a test’s real-world value is dictated by its positive and negative predictive values, which shift based on disease prevalence[68]. To truly demonstrate its worth, the EV-lRNA framework should be subjected to decision curve analysis. By weighing the clinical costs of false positives against the benefits of true positives, decision curve analysis can definitively show whether this new model outperforms the standard carbohydrate antigen 19-9 blood test[69].

To contextualize the framework’s superiority and outline current bottlenecks, Table 1 compares the diagnostic performance metrics of different biomarker approaches for PDAC diagnosis. By summarizing the comparative diagnostic performance of current biomarker strategies for PDAC, this table highlights the advantages and limitations of each approach.

Table 1 Comparative diagnostic performance of biomarker strategies for pancreatic ductal adenocarcinoma.

Biomarker/method	AUC	Sensitivity	Specificity	PPV (30% prevalence)	Key limitations
CA19-9 alone	0.70-0.85[4]	70%-80%	70%-90%	50%-79%	Low early-stage sensitivity; false positives in pancreatitis
EV-miRNA panels	0.85-0.92[42]	75%-85%	80%-90%	64%-79%	Limited specificity; cancer-type overlap
ctDNA mutation	0.65-0.80[12]	50%-70%	85%-95%	59%-84%	Low sensitivity in early disease; requires high-depth sequencing
ECD-itMLF (EV-lRNA)	0.9698[22]	About 90%	About 95%	About 89%	Requires validation in jaundice/diabetes; method standardization needed
Multi-omics integration	0.90-0.95[47]	80%-90%	85%-95%	70%-84%	Complexity; cost; technical standardization

AUC: Area under the curve; PPV: Positive predictive value; EV: Extracellular vesicle; ctDNA: Circulating tumor DNA; miRNA: MicroRNAs; CA19-9: Carbohydrate antigen 19-9; EV-lRNA: Extracellular vesicle long RNA.

Standardization and reproducibility requirements

The transition from discovery to a deployable clinical tool faces significant hurdles in standardization, as variations in EV isolation methodologies remain a substantial source of bias. Batch effects from run-to-run technical variation in sequencing can obscure biological signal[70]. Ensuring that external cohorts spanning diverse centers and processing pipelines are truly independent is essential to rule out the risk of batch effects.

FUTURE PERSPECTIVES

The ECD-itMLF framework establishes a foundation for expanding liquid biopsy applications. Figure 2 illustrates how the future of liquid biopsy lies in the seamless integration of various data modalities. Specifically, this multi-omics approach combining EV-lRNA, ctDNA, and radiomics driven by AI will likely define the next generation of precision oncology (Figure 2).

Figure 2 Future multi-omics integration strategy for pancreatic ductal adenocarcinoma liquid biopsy. Created with Picdoc. The integration of extracellular vesicle long RNA, circulating tumor DNA mutations, extracellular vesicle-derived proteins (GPC1 and CD63), and metabolic profiles enables comprehensive molecular characterization. Artificial intelligence-driven fusion of these layers, combined with radiomic features from medical imaging, promises enhanced diagnostic accuracy and minimal residual disease monitoring. EV: Extracellular vesicle; EV-lRNA: Extracellular vesicle long RNA; ctDNA: Circulating tumor DNA; AI: Artificial intelligence; MRD: Minimal residual disease.

Single-EV resolution technologies

Current bulk EV analyses average signals across heterogeneous populations, potentially diluting tumor-specific signatures. Emerging single-EV technologies promise to resolve this heterogeneity[29]. Single-EV RNA sequencing, enabled by microfluidic approaches, allows transcriptomic analysis of individual EVs, potentially identifying rare tumor cell-derived EVs among abundant non-tumor vesicles.

Multi-analyte integration strategies

The future of liquid biopsy lies not in single-analyte tests but in integrated multi-omics approaches[47]. EV-RNA combined with ctDNA provides complementary information—EVs offer functional pathway insights while ctDNA provides genetic driver events.

Minimal residual disease monitoring

Beyond just detecting primary tumors, the EV-lRNA signature has massive potential for tracking minimal residual disease. Even though the current research targets initial diagnosis, taking longitudinal measurements of these EV markers could theoretically catch a molecular relapse well before any new tumors appear on a scan. This concept closely mirrors how clinicians are increasingly using ctDNA today.

CONCLUSION

Liu and Zhang[22] have provided a major upgrade to liquid biopsies for pancreatic cancer. Their ECD-itMLF framework does not just deliver high diagnostic accuracy; it finally gives clinicians the biological transparency that they need from an AI tool. By successfully pairing probabilistic models—which are perfect for handling sparse, complex data—with direct links to biological pathways, they have set a new standard for EV-based testing. Moving forward, the true test will be large-scale, prospective, multicenter clinical trials. Only then can we confirm if this EV-lRNA approach is genuinely robust, reproducible, and cost-effective enough to compete with today’s standard imaging and established biomarkers.